Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.
about
Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stressHDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulationDietary histone deacetylase inhibitors: from cells to mice to manHistone deacetylase inhibitors: Potential in cancer therapyPCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cellsPotential use of histone deacetylase inhibitors in cancer therapyEGFR Amplification and Glioblastoma Stem-Like CellsMechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer CellsAcetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and CancerEpigenetics in Brain Tumors: HDACs Take Center StageDimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugTrichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy.Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanateThe role of the NADPH oxidase complex, p38 MAPK, and Akt in regulating human monocyte/macrophage survivalTrichostatin A targets the mitochondrial respiratory chain, increasing mitochondrial reactive oxygen species production to trigger apoptosis in human breast cancer cellsMotexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductaseCancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitorPreclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma CellsTargeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA).Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathwayEpigenetic changes in the myelodysplastic syndrome.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivoIdentification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells.Ferritin H induction by histone deacetylase inhibitors.Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.
P2860
Q23918915-8A84C36D-1CA0-4F87-AFFC-A6F500B96A4FQ24310722-2435F77A-EC73-446A-9F2E-43A476036312Q24641899-16E1F17D-600C-44B4-BC22-903EC3394BB3Q24649025-5F29F036-01FD-434F-8CFE-28928E7BAE44Q24654958-12758116-8226-4F3C-90BE-6BD3942D7C9AQ26769594-5BFFC944-78EF-4E48-A46C-F019A0A55F43Q26853549-0928EE82-2277-4FBC-892D-6D9AF9949E41Q27015931-7FBB7624-B1A3-4CC3-A783-41500E869B75Q28076086-6191AD35-70AA-4C5B-9EF4-AA5999B27163Q28080964-ACB8BAC3-4853-4584-84A3-F7F328FBD557Q28282479-A091AE48-19F5-406F-B2D7-4F40354F75C7Q28289793-54528E6B-2269-4E74-9E09-D390A2EE44CEQ28383320-1A50A8E9-E89E-4B98-A1BB-D944566FF91DQ28396081-6037DCB5-539C-4CED-9DBE-E1BE65830BF9Q28540870-8E7137E4-5D80-423C-BF7D-BC5567558703Q28567883-5C02AB03-5524-4136-B0FB-9BF7C7BBDAE9Q28972517-D0BA5AD6-0D5E-4F8A-AFB5-BD05F682F3B7Q30459589-0710AB11-75CD-443B-8514-DAD29778F44BQ30464276-607C8F5C-472D-4EB5-B44B-0A259D008824Q32177411-B18A43BF-64D2-4262-AE98-3CB83DD6ACBCQ33291299-FCA6063C-3132-425B-8DC9-E376CDB0C0ACQ33375694-3FEDAF94-90C4-46D3-9E7C-985C29C56A68Q33385966-BDBB5263-6206-4324-B281-D6573D32373DQ33390876-2A59D17B-E950-4EDB-9157-0174EE633EC7Q33590788-BD5EE629-E307-43C1-8F17-8919B51D5DBBQ33705588-553D02F3-BEEF-4E60-95EC-546463E73239Q33741142-DDE41027-A748-4EBD-8561-F10ADD42C3A9Q33744417-674948CB-CB26-4158-A60A-54B51C116FC8Q33767309-4EE34E12-354D-4626-9F4A-048781013542Q33829390-C19471FC-31EA-4CD9-AFFF-C887EDF7345DQ33838633-60C923F8-2446-48CC-B957-5C55C40A130FQ33863049-DA8A36F9-D184-4752-83E3-73E970331293Q33896749-D29E393D-31E2-4FF8-8D2D-A157081BBF03Q33926864-F0980A9C-245D-46D7-AB83-E6E686F8B84CQ33962243-11971C12-1077-4CA7-B978-490A87B44931Q33983255-93B41443-A818-4747-928B-8A0DDBFEBAD7Q33985807-731D2ACC-2FE3-46A8-91A5-370F7EAB7167Q34034477-F34AB2FC-0848-4B8D-8DB1-ED95845DA09CQ34093052-2E7CC625-65D7-420A-B2F4-AEE1A5A0CF7EQ34115920-2E7738CC-A7CE-4A83-9FB8-E281B97715DF
P2860
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Role of thioredoxin in the res ...... istone deacetylase inhibitors.
@ast
Role of thioredoxin in the res ...... istone deacetylase inhibitors.
@en
type
label
Role of thioredoxin in the res ...... istone deacetylase inhibitors.
@ast
Role of thioredoxin in the res ...... istone deacetylase inhibitors.
@en
prefLabel
Role of thioredoxin in the res ...... istone deacetylase inhibitors.
@ast
Role of thioredoxin in the res ...... istone deacetylase inhibitors.
@en
P2093
P2860
P356
P1476
Role of thioredoxin in the res ...... istone deacetylase inhibitors.
@en
P2093
A Holmgren
J S Ungerstedt
M Dokmanovic
P2860
P304
P356
10.1073/PNAS.0408732102
P407
P577
2005-01-06T00:00:00Z